Amgen Inc. (BMV:AMGN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 3.87T +34.4% |
| Revenue (ttm) | 665.65B +9.1% |
| Net Income | 152.77B +32.1% |
| EPS | 281.23 +31.6% |
| Shares Out | n/a |
| PE Ratio | 25.31 |
| Forward PE | 17.75 |
| Dividend | 175.20 (2.61%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 939 |
| Open | 6,710.00 |
| Previous Close | n/a |
| Day's Range | 6,710.00 - 6,710.00 |
| 52-Week Range | 5,023.00 - 6,718.00 |
| Beta | 0.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Amgen price target raised to $388 from $343 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Amgen (AMGN) to $388 from $343 and keeps a Neutral rating on the shares after updating the firm’s model following…
Amgen price target raised to $405 from $345 at Citi
Citi raised the firm’s price target on Amgen (AMGN) to $405 from $345 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q2…
Amgen price target raised to $345 from $335 at Bernstein
Bernstein raised the firm’s price target on Amgen (AMGN) to $345 from $335 and keeps a Market Perform rating on the shares. Amgen reported another strong quarter, with a 6.8%…
Amgen price target raised to $450 from $385 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $450 from $385 and keeps an Outperform rating on the shares. The firm remains positive on the…
Amgen price target raised to $362 from $340 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Amgen (AMGN) to $362 from $340 and keeps a Hold rating on the shares. Amgen delivered strong Q2 results with…
Amgen price target raised to $440 from $420 at UBS
UBS raised the firm’s price target on Amgen (AMGN) to $440 from $420 and keeps a Buy rating on the shares. Amgen posted a “solid” beat and slight raise, the…
Amgen price target raised to $452 from $420 at TD Cowen
TD Cowen raised the firm’s price target on Amgen (AMGN) to $452 from $420 and keeps a Buy rating on the shares. The firm updated its model following its beat…
Amgen price target raised to $450 from $400 at Oppenheimer
Oppenheimer raised the firm’s price target on Amgen (AMGN) to $450 from $400 and keeps an Outperform rating on the shares. The firm notes the company delivered strong Q2 results…
Amgen price target raised to $351 from $333 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $351 from $333 and keeps an Equal Weight rating on the shares. A Q2 beat was driven by a…
Amgen price target raised to $400 from $370 at RBC Capital
RBC Capital raised the firm’s price target on Amgen (AMGN) to $400 from $370 and keeps an Outperform rating on the shares. Amgen delivered a significant Q2 beat and raised…
Amgen price target raised to $317 from $312 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Amgen (AMGN) to $317 from $312 and keeps an Underperform rating on the shares. While the firm acknowledges the company’s…
Amgen price target raised to $230 from $215 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Amgen (AMGN) to $230 from $215 and keeps an Underperform rating on the shares. The firm updated its model following…
Amgen price target raised to $384 from $366 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on Amgen (AMGN) to $384 from $366 and keeps a Hold rating on the shares. The firm updated its model following…
Amgen price target raised to $450 from $400 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Amgen (AMGN) to $450 from $400 and keeps an Outperform rating on the shares. Amgen delivered a strong commercial…
Amgen price target raised to $400 from $390 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $400 from $390 and keeps an Equal Weight rating on the shares. The firm notes the…
Amgen Earnings Call Transcript: Q2 2026
Q2 2026 revenues rose 10% year-over-year to over $10 billion, driven by strong growth across six key product areas, with 22 products posting double-digit sales gains. Guidance for 2026 was raised, reflecting robust execution, expanding pipeline, and continued investment in innovation.
Amgen Earnings release: Q2 2026
Amgen released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Amgen Slides: Q2 2026
Amgen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Amgen Quarterly report: Q2 2026
Amgen has published its Q2 2026 quarterly earnings report on August 4, 2026.
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment
The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.
Amgen reports Q2 adjusted EPS $6.29, consensus $5.62
Reports Q2 revenue $10.1B, consensus $9.42B. “Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarte...
Amgen raises FY26 adjusted EPS view to $22.30-$23.50 from $21.70-$23.10
FY26 consensus $22.35. Raises FY26 revenue view to $38.2B-$39.4B from $37.1B-$38.5B, consensus $37.74B.
Amgen second-quarter sales rise 9%, profit tops Street view
Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop experim...
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026.
Amgen discloses data breach, says patient information was stolen
Drugmaker Amgen suffered a cybersecurity breach where hackers stole company data and patient health information from cloud storage systems run by third-party providers, it said in a regu...